Bruce Booth, Director at Kymera Therapeutics, Inc. (KYMR), sold 513,245 shares at $107.57 ($56.5M) on 2026-06-26, disclosed to the SEC on 2026-06-30.
Scheduled sale ($56.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $107.57 | 3,958 | $426K | 0.8% |
| 2 | $107.57 | 28,296 | $3.0M | 5.4% |
| 3 | $108.14 | 231,007 | $25.0M | 44.2% |
| 4 | $108.14 | 32,402 | $3.5M | 6.2% |
| 5 | $109.79 | 4,562 | $501K | 0.9% |
| 6 | $109.79 | 32,624 |
| $3.6M |
| 6.3% |
| 7 | $110.49 | 1,579 | $174K | 0.3% |
| 8 | $110.49 | 11,277 | $1.2M | 2.2% |
| 9 | $111.51 | 1,442 | $161K | 0.3% |
| 10 | $111.51 | 10,366 | $1.2M | 2.0% |
| 11 | $112.49 | 78 | $9K | 0.0% |
| 12 | $112.49 | 555 | $62K | 0.1% |
| 13 | $113.97 | 14,913 | $1.7M | 3.0% |
| 14 | $113.97 | 2,083 | $237K | 0.4% |
| 15 | $114.94 | 3,896 | $448K | 0.8% |
| 16 | $114.94 | 27,951 | $3.2M | 5.7% |
| 17 | $115.69 | 6,821 | $789K | 1.4% |
| 18 | $115.69 | 952 | $110K | 0.2% |
| 19 | $117.09 | 12,181 | $1.4M | 2.5% |
| 20 | $117.09 | 1,701 | $199K | 0.4% |
| 21 | $117.85 | 3,069 | $362K | 0.6% |
| 22 | $117.85 | 22,046 | $2.6M | 4.6% |
| 23 | $118.66 | 12,390 | $1.5M | 2.6% |
| 24 | $118.66 | 1,729 | $205K | 0.4% |
| 25 | $105.78 | 5,471 | $579K | 1.0% |
| 26 | $105.78 | 848 | $90K | 0.2% |
| 27 | $106.63 | 2,318 | $247K | 0.4% |
| 28 | $106.63 | 14,613 | $1.6M | 2.8% |
| 29 | $107.76 | 19,093 | $2.1M | 3.6% |
| 30 | $107.76 | 3,024 | $326K | 0.6% |
| Total | $110.01 avg | 513,245 | $56.5M | 100% |
| Filing → |
| KYMR | SELL | 2026-06-25 | $34.8M | — | Filing → |
| KYMR | SELL | 2026-06-25 | $44.0M | — | Filing → |
| KYMR | SELL | 2026-06-22 | $45.3M | — | Filing → |